Inclusion Criteria:

- Histologically verified locally advanced T3 or T4 colon cancer assessed by CT scan

- Analysis of KRAS, BRAF, PIK3CA

- Age ≥18 år

- Performance status ≤ 2

- Hematology

- ANC ≥ 1.5x10^9/l. Thrombocytes ≥ 100x10^9/l.

- Biochemistry

- Bilirubinaemia ≤ 3 x UNL. ALAT ≤ 5 x UNL

- Consent to translational research

- Fertile women must present a negative pregnancy test and use secure birth control
during and 3 months after treatment.

- Written and orally informed consent.

Exclusion Criteria:

- Clinically significant cardiovascular disease (including myocardial infarction,
unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac
arrhythmia) ≤ 1 year before enrollment, active severe infections or other concurrent
disease.

- Peripheral neuropathy NCI grade >1

- Other malignant disease within 5 years prior to enrollment, except basal cell
squamous carcinoma of the skin and cervical carcinoma-in-situ

- Other investigational treatment within 30 days prior to treatment start

- History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or
evidence of interstitial lung disease on baseline chest CT scan.

- Bleeding tumors

- Hypersensitivity to one or more of the substances